Topic: Cardiovascular
Conditions
Interventions
Patients will receive, in a random order, 5 blocks of 5 week treatments consisting of:
1. Bendroflumethiazide 2.5 - 5 mg
2. Amiloride 20 - 40 mg
3. Spir
Sponsors
Cambridge University Hospitals NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 - 45 years 2. Male or female 3. Hypertensive: 3.1. Three clinic systolic blood pressure (SBP) greater than or equal to 140 mmHg; or 3.2. Three clinic diastolic blood pressure (DBP) greater than or equal to 90 mmHg; or 3.3. Ambulatory blood pressure monitoring (ABPM) or home blood pressure (BP) greater than or equal to 130 mmHg (SBP) or 85 mmHg (DBP) 4. 24-hour Na+ less than 160 mmol/l 5. Either: 5.1. Plasma renin less than or equal to 10 mU/L (measured untreated, or whilst receiving only CCB+/-diuretic) + plasma renin less than or equal to 40 mU/L (measured on an ACEi or ARB, which approximately doubles the plasma renin); or 5.2. Plasma renin less than 5 mU/L (measure untreated) 6. Receiving any antihypertensive drug other than a beta-blocker
Exclusion criteria
Exclusion criteria: 1. Documented history of gout 2. Abnormal renal function (both elevated serum creatinine and reduced creatinine clearance) 3. SBP greater than 170 mmHg or DBP greater than 110 mmHg despite treatment with permitted background treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in the fall in systolic blood pressure for each participant's best and second best drug | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed